|
Gene: TMEM140 |
Gene summary for TMEM140 |
Gene summary. |
Gene information | Species | Human | Gene symbol | TMEM140 | Gene ID | 55281 |
Gene name | transmembrane protein 140 | |
Gene Alias | TMEM140 | |
Cytomap | 7q33 | |
Gene Type | protein-coding | GO ID | GO:0005575 | UniProtAcc | Q9NV12 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
55281 | TMEM140 | HCC1_Meng | Human | Liver | HCC | 2.85e-26 | 2.27e-02 | 0.0246 |
55281 | TMEM140 | cirrhotic2 | Human | Liver | Cirrhotic | 1.66e-07 | 1.91e-01 | 0.0201 |
55281 | TMEM140 | HCC1 | Human | Liver | HCC | 6.46e-05 | 2.81e+00 | 0.5336 |
55281 | TMEM140 | S014 | Human | Liver | HCC | 8.92e-04 | 3.86e-01 | 0.2254 |
55281 | TMEM140 | S015 | Human | Liver | HCC | 7.24e-03 | 4.10e-01 | 0.2375 |
55281 | TMEM140 | S016 | Human | Liver | HCC | 2.11e-05 | 3.38e-01 | 0.2243 |
55281 | TMEM140 | S028 | Human | Liver | HCC | 2.90e-05 | 5.76e-01 | 0.2503 |
55281 | TMEM140 | S029 | Human | Liver | HCC | 1.89e-13 | 8.57e-01 | 0.2581 |
Page: 1 |
Transcriptomic changes along malignancy continuum. |
Tissue | Expression Dynamics | Abbreviation |
Liver | HCC: Hepatocellular carcinoma | |
NAFLD: Non-alcoholic fatty liver disease |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Stomach | WIM | |
Stomach | SIM | |
Liver | NAFLD | |
Liver | Cirrhotic | |
Liver | HCC |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
TMEM140 | SNV | Missense_Mutation | novel | c.310G>C | p.Ala104Pro | p.A104P | Q9NV12 | protein_coding | deleterious(0.02) | probably_damaging(0.948) | TCGA-A7-A4SE-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | CR |
TMEM140 | SNV | Missense_Mutation | novel | c.543G>T | p.Lys181Asn | p.K181N | Q9NV12 | protein_coding | deleterious_low_confidence(0.05) | benign(0.12) | TCGA-E9-A1R2-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | taxotere | CR |
TMEM140 | SNV | Missense_Mutation | rs143180494 | c.265N>A | p.Gly89Arg | p.G89R | Q9NV12 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-C5-A1BQ-01 | Cervix | cervical & endocervical cancer | Female | >=65 | III/IV | Chemotherapy | cisplatin | CR |
TMEM140 | SNV | Missense_Mutation | c.236N>A | p.Gly79Asp | p.G79D | Q9NV12 | protein_coding | deleterious(0.01) | probably_damaging(0.955) | TCGA-CK-6746-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
TMEM140 | SNV | Missense_Mutation | rs150916088 | c.388N>A | p.Gly130Ser | p.G130S | Q9NV12 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-CM-5349-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
TMEM140 | SNV | Missense_Mutation | rs776496054 | c.7N>A | p.Gly3Ser | p.G3S | Q9NV12 | protein_coding | tolerated(0.86) | benign(0.003) | TCGA-D5-6540-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
TMEM140 | deletion | Frame_Shift_Del | c.295delC | p.Gln99SerfsTer5 | p.Q99Sfs*5 | Q9NV12 | protein_coding | TCGA-AA-3947-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |||
TMEM140 | deletion | Frame_Shift_Del | c.290delN | p.Gln99SerfsTer5 | p.Q99Sfs*5 | Q9NV12 | protein_coding | TCGA-G4-6320-01 | Colorectum | colon adenocarcinoma | Male | >=65 | III/IV | Chemotherapy | oxaliplatin | SD | |||
TMEM140 | SNV | Missense_Mutation | rs150916088 | c.388N>A | p.Gly130Ser | p.G130S | Q9NV12 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-E6-A1LX-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
TMEM140 | SNV | Missense_Mutation | novel | c.316N>C | p.Cys106Arg | p.C106R | Q9NV12 | protein_coding | tolerated(0.09) | benign(0.063) | TCGA-EO-A3KX-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |